Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions

Inclusion Criteria: * Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in CABG * Written, informed consent by the patient or her/his legally-authorized representative for participation in the study. * In women with childbearing potential a negative pregnancy test is mandatory Exclusion Criteria: * Cardiogenic shock * Target lesion located in the native coronary vessels. * In-stent restenosis of CABG * Target lesion located at internal mammary artery graft or free arterial graft * Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. * Known allergy to the study medications: clopidogrel, rapamycin, paclitaxel, stainless steel. * Inability to take clopidogrel for at least 6 months. * Pregnancy (present, suspected or planned) or positive pregnancy test. * Previous enrollment in this trial. * Patient's inability to fully cooperate with the study protocol.